Compare OMDA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMDA | PCRX |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2025 | 2010 |
| Metric | OMDA | PCRX |
|---|---|---|
| Price | $20.41 | $25.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $28.42 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 936.3K | 424.0K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 94.27 | ★ 107.44 |
| EPS | 0.04 | ★ 0.19 |
| Revenue | $260,210,000.00 | ★ $541,533,000.00 |
| Revenue This Year | $30.15 | $3.85 |
| Revenue Next Year | $20.42 | $4.69 |
| P/E Ratio | $489.50 | ★ $134.42 |
| Revenue Growth | ★ 53.24 | 26.04 |
| 52 Week Low | $10.28 | $18.80 |
| 52 Week High | $26.92 | $27.66 |
| Indicator | OMDA | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 51.01 |
| Support Level | $19.31 | $22.13 |
| Resistance Level | $21.52 | $27.03 |
| Average True Range (ATR) | 0.85 | 0.84 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 74.17 | 68.38 |
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.